Independent reference. Not affiliated with, endorsed by, or speaking for the U.S. Food and Drug Administration.

← All approvals · Cancer · 2024

Imdelltra (tarlatamab-dlle)

The FDA approved Imdelltra (tarlatamab-dlle) on May 16, 2024 to treat extensive stage small cell lung cancer.

Brand name: Imdelltra
Generic name: tarlatamab-dlle
FDA approval date: May 16, 2024
Approved use (FDA wording): To treat extensive stage small cell lung cancer
Category on this site: Cancer

Official sources

FDA novel drug approvals list
FDA announcement

Facts only. This site lists what the FDA has approved and what the FDA says each drug is approved for, quoted or closely paraphrased from FDA and openFDA records. It gives no medical advice, no dosing, and no comparisons, and it says nothing about whether a drug is right for anyone. Talk to a licensed clinician about any medication. Records can lag or contain errors; the FDA's own pages are authoritative.